Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Mural Oncology, Inc
AbbVie
Universitaire Ziekenhuizen KU Leuven
M.D. Anderson Cancer Center
NRG Oncology
Mayo Clinic
Hoffmann-La Roche
Fox Chase Cancer Center
M.D. Anderson Cancer Center
University of Miami
Canadian Cancer Trials Group
pharmaand GmbH
Hoffmann-La Roche
M.D. Anderson Cancer Center
University of Virginia
National Cancer Institute (NCI)
University of Washington
GOG Foundation
GOG Foundation
GOG Foundation
Columbia University
Eli Lilly and Company
ImmunoGen, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Medical University Innsbruck
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Takeda
UConn Health
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Alliance for Clinical Trials in Oncology
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals
Memorial Sloan Kettering Cancer Center